Cargando…

Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients

BACKGROUND: The diagnostic and pathophysiological relevance of antibodies to aquaporin-4 (AQP4-Ab) in patients with neuromyelitis optica spectrum disorders (NMOSD) has been intensively studied. However, little is known so far about the clinical impact of AQP4-Ab seropositivity. OBJECTIVE: To analyse...

Descripción completa

Detalles Bibliográficos
Autores principales: Jarius, Sven, Ruprecht, Klemens, Wildemann, Brigitte, Kuempfel, Tania, Ringelstein, Marius, Geis, Christian, Kleiter, Ingo, Kleinschnitz, Christoph, Berthele, Achim, Brettschneider, Johannes, Hellwig, Kerstin, Hemmer, Bernhard, Linker, Ralf A, Lauda, Florian, Mayer, Christoph A, Tumani, Hayrettin, Melms, Arthur, Trebst, Corinna, Stangel, Martin, Marziniak, Martin, Hoffmann, Frank, Schippling, Sven, Faiss, Jürgen H, Neuhaus, Oliver, Ettrich, Barbara, Zentner, Christian, Guthke, Kersten, Hofstadt-van Oy, Ulrich, Reuss, Reinhard, Pellkofer, Hannah, Ziemann, Ulf, Kern, Peter, Wandinger, Klaus P, Bergh, Florian Then, Boettcher, Tobias, Langel, Stefan, Liebetrau, Martin, Rommer, Paulus S, Niehaus, Sabine, Münch, Christoph, Winkelmann, Alexander, Zettl U, Uwe K, Metz, Imke, Veauthier, Christian, Sieb, Jörn P, Wilke, Christian, Hartung, Hans P, Aktas, Orhan, Paul, Friedemann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3283476/
https://www.ncbi.nlm.nih.gov/pubmed/22260418
http://dx.doi.org/10.1186/1742-2094-9-14
_version_ 1782224193055621120
author Jarius, Sven
Ruprecht, Klemens
Wildemann, Brigitte
Kuempfel, Tania
Ringelstein, Marius
Geis, Christian
Kleiter, Ingo
Kleinschnitz, Christoph
Berthele, Achim
Brettschneider, Johannes
Hellwig, Kerstin
Hemmer, Bernhard
Linker, Ralf A
Lauda, Florian
Mayer, Christoph A
Tumani, Hayrettin
Melms, Arthur
Trebst, Corinna
Stangel, Martin
Marziniak, Martin
Hoffmann, Frank
Schippling, Sven
Faiss, Jürgen H
Neuhaus, Oliver
Ettrich, Barbara
Zentner, Christian
Guthke, Kersten
Hofstadt-van Oy, Ulrich
Reuss, Reinhard
Pellkofer, Hannah
Ziemann, Ulf
Kern, Peter
Wandinger, Klaus P
Bergh, Florian Then
Boettcher, Tobias
Langel, Stefan
Liebetrau, Martin
Rommer, Paulus S
Niehaus, Sabine
Münch, Christoph
Winkelmann, Alexander
Zettl U, Uwe K
Metz, Imke
Veauthier, Christian
Sieb, Jörn P
Wilke, Christian
Hartung, Hans P
Aktas, Orhan
Paul, Friedemann
author_facet Jarius, Sven
Ruprecht, Klemens
Wildemann, Brigitte
Kuempfel, Tania
Ringelstein, Marius
Geis, Christian
Kleiter, Ingo
Kleinschnitz, Christoph
Berthele, Achim
Brettschneider, Johannes
Hellwig, Kerstin
Hemmer, Bernhard
Linker, Ralf A
Lauda, Florian
Mayer, Christoph A
Tumani, Hayrettin
Melms, Arthur
Trebst, Corinna
Stangel, Martin
Marziniak, Martin
Hoffmann, Frank
Schippling, Sven
Faiss, Jürgen H
Neuhaus, Oliver
Ettrich, Barbara
Zentner, Christian
Guthke, Kersten
Hofstadt-van Oy, Ulrich
Reuss, Reinhard
Pellkofer, Hannah
Ziemann, Ulf
Kern, Peter
Wandinger, Klaus P
Bergh, Florian Then
Boettcher, Tobias
Langel, Stefan
Liebetrau, Martin
Rommer, Paulus S
Niehaus, Sabine
Münch, Christoph
Winkelmann, Alexander
Zettl U, Uwe K
Metz, Imke
Veauthier, Christian
Sieb, Jörn P
Wilke, Christian
Hartung, Hans P
Aktas, Orhan
Paul, Friedemann
author_sort Jarius, Sven
collection PubMed
description BACKGROUND: The diagnostic and pathophysiological relevance of antibodies to aquaporin-4 (AQP4-Ab) in patients with neuromyelitis optica spectrum disorders (NMOSD) has been intensively studied. However, little is known so far about the clinical impact of AQP4-Ab seropositivity. OBJECTIVE: To analyse systematically the clinical and paraclinical features associated with NMO spectrum disorders in Caucasians in a stratified fashion according to the patients' AQP4-Ab serostatus. METHODS: Retrospective study of 175 Caucasian patients (AQP4-Ab positive in 78.3%). RESULTS: Seropositive patients were found to be predominantly female (p < 0.0003), to more often have signs of co-existing autoimmunity (p < 0.00001), and to experience more severe clinical attacks. A visual acuity of ≤ 0.1 during acute optic neuritis (ON) attacks was more frequent among seropositives (p < 0.002). Similarly, motor symptoms were more common in seropositive patients, the median Medical Research Council scale (MRC) grade worse, and MRC grades ≤ 2 more frequent, in particular if patients met the 2006 revised criteria (p < 0.005, p < 0.006 and p < 0.01, respectively), the total spinal cord lesion load was higher (p < 0.006), and lesions ≥ 6 vertebral segments as well as entire spinal cord involvement more frequent (p < 0.003 and p < 0.043). By contrast, bilateral ON at onset was more common in seronegatives (p < 0.007), as was simultaneous ON and myelitis (p < 0.001); accordingly, the time to diagnosis of NMO was shorter in the seronegative group (p < 0.029). The course of disease was more often monophasic in seronegatives (p < 0.008). Seropositives and seronegatives did not differ significantly with regard to age at onset, time to relapse, annualized relapse rates, outcome from relapse (complete, partial, no recovery), annualized EDSS increase, mortality rate, supratentorial brain lesions, brainstem lesions, history of carcinoma, frequency of preceding infections, oligoclonal bands, or CSF pleocytosis. Both the time to relapse and the time to diagnosis was longer if the disease started with ON (p < 0.002 and p < 0.013). Motor symptoms or tetraparesis at first myelitis and > 1 myelitis attacks in the first year were identified as possible predictors of a worse outcome. CONCLUSION: This study provides an overview of the clinical and paraclinical features of NMOSD in Caucasians and demonstrates a number of distinct disease characteristics in seropositive and seronegative patients.
format Online
Article
Text
id pubmed-3283476
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-32834762012-02-22 Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients Jarius, Sven Ruprecht, Klemens Wildemann, Brigitte Kuempfel, Tania Ringelstein, Marius Geis, Christian Kleiter, Ingo Kleinschnitz, Christoph Berthele, Achim Brettschneider, Johannes Hellwig, Kerstin Hemmer, Bernhard Linker, Ralf A Lauda, Florian Mayer, Christoph A Tumani, Hayrettin Melms, Arthur Trebst, Corinna Stangel, Martin Marziniak, Martin Hoffmann, Frank Schippling, Sven Faiss, Jürgen H Neuhaus, Oliver Ettrich, Barbara Zentner, Christian Guthke, Kersten Hofstadt-van Oy, Ulrich Reuss, Reinhard Pellkofer, Hannah Ziemann, Ulf Kern, Peter Wandinger, Klaus P Bergh, Florian Then Boettcher, Tobias Langel, Stefan Liebetrau, Martin Rommer, Paulus S Niehaus, Sabine Münch, Christoph Winkelmann, Alexander Zettl U, Uwe K Metz, Imke Veauthier, Christian Sieb, Jörn P Wilke, Christian Hartung, Hans P Aktas, Orhan Paul, Friedemann J Neuroinflammation Research BACKGROUND: The diagnostic and pathophysiological relevance of antibodies to aquaporin-4 (AQP4-Ab) in patients with neuromyelitis optica spectrum disorders (NMOSD) has been intensively studied. However, little is known so far about the clinical impact of AQP4-Ab seropositivity. OBJECTIVE: To analyse systematically the clinical and paraclinical features associated with NMO spectrum disorders in Caucasians in a stratified fashion according to the patients' AQP4-Ab serostatus. METHODS: Retrospective study of 175 Caucasian patients (AQP4-Ab positive in 78.3%). RESULTS: Seropositive patients were found to be predominantly female (p < 0.0003), to more often have signs of co-existing autoimmunity (p < 0.00001), and to experience more severe clinical attacks. A visual acuity of ≤ 0.1 during acute optic neuritis (ON) attacks was more frequent among seropositives (p < 0.002). Similarly, motor symptoms were more common in seropositive patients, the median Medical Research Council scale (MRC) grade worse, and MRC grades ≤ 2 more frequent, in particular if patients met the 2006 revised criteria (p < 0.005, p < 0.006 and p < 0.01, respectively), the total spinal cord lesion load was higher (p < 0.006), and lesions ≥ 6 vertebral segments as well as entire spinal cord involvement more frequent (p < 0.003 and p < 0.043). By contrast, bilateral ON at onset was more common in seronegatives (p < 0.007), as was simultaneous ON and myelitis (p < 0.001); accordingly, the time to diagnosis of NMO was shorter in the seronegative group (p < 0.029). The course of disease was more often monophasic in seronegatives (p < 0.008). Seropositives and seronegatives did not differ significantly with regard to age at onset, time to relapse, annualized relapse rates, outcome from relapse (complete, partial, no recovery), annualized EDSS increase, mortality rate, supratentorial brain lesions, brainstem lesions, history of carcinoma, frequency of preceding infections, oligoclonal bands, or CSF pleocytosis. Both the time to relapse and the time to diagnosis was longer if the disease started with ON (p < 0.002 and p < 0.013). Motor symptoms or tetraparesis at first myelitis and > 1 myelitis attacks in the first year were identified as possible predictors of a worse outcome. CONCLUSION: This study provides an overview of the clinical and paraclinical features of NMOSD in Caucasians and demonstrates a number of distinct disease characteristics in seropositive and seronegative patients. BioMed Central 2012-01-19 /pmc/articles/PMC3283476/ /pubmed/22260418 http://dx.doi.org/10.1186/1742-2094-9-14 Text en Copyright ©2012 Jarius et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Jarius, Sven
Ruprecht, Klemens
Wildemann, Brigitte
Kuempfel, Tania
Ringelstein, Marius
Geis, Christian
Kleiter, Ingo
Kleinschnitz, Christoph
Berthele, Achim
Brettschneider, Johannes
Hellwig, Kerstin
Hemmer, Bernhard
Linker, Ralf A
Lauda, Florian
Mayer, Christoph A
Tumani, Hayrettin
Melms, Arthur
Trebst, Corinna
Stangel, Martin
Marziniak, Martin
Hoffmann, Frank
Schippling, Sven
Faiss, Jürgen H
Neuhaus, Oliver
Ettrich, Barbara
Zentner, Christian
Guthke, Kersten
Hofstadt-van Oy, Ulrich
Reuss, Reinhard
Pellkofer, Hannah
Ziemann, Ulf
Kern, Peter
Wandinger, Klaus P
Bergh, Florian Then
Boettcher, Tobias
Langel, Stefan
Liebetrau, Martin
Rommer, Paulus S
Niehaus, Sabine
Münch, Christoph
Winkelmann, Alexander
Zettl U, Uwe K
Metz, Imke
Veauthier, Christian
Sieb, Jörn P
Wilke, Christian
Hartung, Hans P
Aktas, Orhan
Paul, Friedemann
Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients
title Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients
title_full Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients
title_fullStr Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients
title_full_unstemmed Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients
title_short Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients
title_sort contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3283476/
https://www.ncbi.nlm.nih.gov/pubmed/22260418
http://dx.doi.org/10.1186/1742-2094-9-14
work_keys_str_mv AT jariussven contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients
AT ruprechtklemens contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients
AT wildemannbrigitte contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients
AT kuempfeltania contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients
AT ringelsteinmarius contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients
AT geischristian contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients
AT kleiteringo contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients
AT kleinschnitzchristoph contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients
AT bertheleachim contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients
AT brettschneiderjohannes contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients
AT hellwigkerstin contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients
AT hemmerbernhard contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients
AT linkerralfa contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients
AT laudaflorian contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients
AT mayerchristopha contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients
AT tumanihayrettin contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients
AT melmsarthur contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients
AT trebstcorinna contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients
AT stangelmartin contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients
AT marziniakmartin contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients
AT hoffmannfrank contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients
AT schipplingsven contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients
AT faissjurgenh contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients
AT neuhausoliver contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients
AT ettrichbarbara contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients
AT zentnerchristian contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients
AT guthkekersten contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients
AT hofstadtvanoyulrich contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients
AT reussreinhard contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients
AT pellkoferhannah contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients
AT ziemannulf contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients
AT kernpeter contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients
AT wandingerklausp contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients
AT berghflorianthen contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients
AT boettchertobias contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients
AT langelstefan contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients
AT liebetraumartin contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients
AT rommerpauluss contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients
AT niehaussabine contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients
AT munchchristoph contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients
AT winkelmannalexander contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients
AT zettluuwek contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients
AT metzimke contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients
AT veauthierchristian contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients
AT siebjornp contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients
AT wilkechristian contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients
AT hartunghansp contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients
AT aktasorhan contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients
AT paulfriedemann contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients